Pharmacogenomics may improve health outcomes and mitigate risks: one test lasts a lifetime.
Pharmacogenomics (PGx) is designed to provide information on a person’s genetic makeup that may be useful for physicians’ decision-making1. Physicians receive quality assured test results in a comprehensive, reader-friendly report that may be useful in determining which medications and doses are more likely to work, reducing risk, time, and cost for effective treatment.
An AEON Labs phlebotomist will take a blood or urine sample from the patient, to be processed in our laboratories. Our team will look for changes or variants in genes that can affect drug receptors, drug uptake or drug breakdown.
PGx is typically ordered under one of these circumstances:
Patients have multiple medications
Prior to starting specific drug therapy that may have preventable adverse effects (~350,000 adverse reactions occur annually in nursing homes2)
If a person has started a drug and is experiencing side effects
Challenges exist with dosage
Specimen type: Whole Blood, Buccal, or Saliva (collected at AEON or onsite by appointment)
Results: Up to 64 different genes are analyzed with results reported within 14 days
AEON’s System: PGx TaqMan® array plates are 384-well format plates that contain pre-plated, dried down TaqMan® Genotyping Assays. The 384-well TaqMan® Array PGx Express panel plate contains 64 pre-selected, wet-lab validated TaqMan® DME (drug metabolizing enzymes) and SNP (single nucleotide polymorphism) genotyping assays.
Interested in learning more about PGx testing?
Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK (2017) Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial. PLoS ONE 12(2): e0170905. https://doi.org/10.1371/journal.pone.0170905
US Food & Drug Administration (FDA). Preventable adverse drug reactions: a focus on drug interactions.https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm. Updated March 6, 2018.